SMS Pharmaceuticals Share Price Analyzed

SMS Pharmaceuticals saw its share price jump on Wednesday, rising by 8.48% to reach a high of ₹297.25 per share. At 10:40 AM, the stock was trading at ₹292.55, with the BSE Sensex up 0.73%.

Key Points

• USFDA approved Ranitidine tablets for acid reflux treatment.
• This approval ended a 5-year absence in the US market.
• Strong financial results: 23% revenue growth and 80% PAT increase.
• Backward integration boosted profit margins significantly.
• The company aims for 20% revenue growth and 20% EBITDA by FY26.
• SMS Pharmaceuticals has facilities in Hyderabad and Vizag with high production capacity.

The increase in SMS Pharmaceuticals’ share price is mainly due to good news: the US Food and Drug Administration (USFDA) gave the okay for a new version of the medicine, Ranitidine tablets. These tablets are used to treat heartburn and stomach problems. This is exciting news because the medicine hadn’t been available in the United States for five years.

Ranitidine tablets help reduce too much acid in the stomach. This approval means people who need this medicine can finally get it back on the market. The company believes this will help many people get better.

SMS Pharmaceuticals had some really good financial results recently. Their sales increased by 23% compared to last year, and their profits jumped by 80%. This was thanks to smart business moves and producing more medicine themselves (called backward integration).

The company plans to keep growing and making more money. They want to grow their sales by 20% and increase their profit margins to 20% by the year 2026. This is being done by continuing to improve their products and production methods.

SMS Pharmaceuticals started in 1990 and is a company that makes the ingredients for medicines (called APIs) and other chemicals. They have two big factories in Hyderabad and Vizag that can make a lot of medicine. They sell their products to customers in over 70 countries.

“We concluded Q2FY26 on a strong note with 80 per cent PAT growth Y-o-Y. We continued to see strong demand across our diversified portfolio, with market share gains in key APIs driving revenue growth. This quarter marks an inflection point as our backward integration efforts are now driving margin expansion. This has strengthened our value proposition to existing customers and is helping us expand our customer base in regulated markets. Our continued focus on product mix optimisation, backward integration, economies of scale and pipeline of new products will enable us to achieve our target of 20 per cent revenue growth and Ebitda margin expansion to 20 per cent in FY26,” Krishna added.

“Our continued focus on product mix optimisation, backward integration, economies of scale and pipeline of new products will enable us to achieve our target of 20 per cent revenue growth and Ebitda margin expansion to 20 per cent in FY26,” Krishna added.

The company’s long-term strategy focuses on sustainable growth through innovation and operational excellence.